Nipah Virus Testing Market Size Worth $3036.68 Million By 2032 | CAGR: 5.1%

Nipah Virus Testing Market Size Worth $3036.68 Million By 2032 | CAGR: 5.1%


The global nipah virus testing market size is expected to reach USD 3,036.68 million by 2032, according to a new study by Polaris Market Research. The report “Nipah Virus Testing Market Share, Size, Trends, Industry Analysis Report, By Sample (Blood, Throat & Nasal Swab, Urine, and Others); By Product Type; By End-User; By Region; Segment Forecast, 2019 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing proliferation towards introducing several new and more advanced point-of-care blood tests and continuously growing demand for immunoassay reagents & kits for the diagnosis purpose coupled with the widespread availability of technologically innovated diagnostic techniques, has been propelling the demand and growth of the market.  Growing development of multiplex testing platforms that can detect multiple viruses simultaneously which also could be important for rapid and accurate diagnosis of Nipah virus, is likely to contribute positively towards the market growth.

For instance, in April 2023, Molbio Diagnostics, announced the launch of its new Truenat test, maily developed for H3N2 and H1N1 virus, that is approved by Central Drugs Standard Control Organization and could also provide sample-to-result in just an hour’s time.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/nipah-virus-testing-market/request-for-sample

The rapid development of reverse transcription polymerase chain reaction assays by researchers across the globe, that can detect Nipah virus RNA which are highly sensitive and specific, and could detect the virus even in low concentrations is creating huge growth potential for the market. Beside this, surging penetration regarding the use serological assays mainly to discover past or current infections, which can be useful for surveillance and epidemiological studies is likely to foster the market in the near future.

Furthermore, growing integration of AI and ML algorithms in order to help analyze large datasets of Nipah virus genomic information is gaining significant traction in the recent years. These tools are also being widely used by researchers specially to identify key genetic markers of the virus, which could inform the development of better diagnostic tests and treatments.

Nipah Virus Testing Market Report Highlights

  • Blood segment held the maximum market revenue share in 2022, on account of widespread use of the sample due to its high reliability and provide better accuracy of virus detection
  • ELISA Kits segment accounted for largest market share, mainly due to increased usage to manage several types of disease markers and also allow the quantitative measurements for the antigens
  • Hospitals segment dominated the global market with substantial share in 2022, which is mainly driven increased expenditure on making these tests available in hospitals across the globe
  • Asia Pacific region is anticipated to grow at fastest growth rate over the study period, owing to growing investment by both government and private healthcare institutions and focus on availing these testing services across the region
  • The global key market players include Roche Diagnostics, Starlake Bioscience, Novartis, Creative Diagnostics, Roche, GenMark Diagnostics, and Merck

Polaris Market Research has segmented the Nipah virus testing market report based on sample, product, end-user, and region:

Nipah Virus Testing, Sample Outlook (Revenue - USD Million, 2019 - 2032)

  • Blood
  • Throat & Nasal Swab
  • Urine
  • Others

Nipah Virus Testing, Product Type Outlook (Revenue - USD Million, 2019 - 2032)

  • ELISA Kits
  • RT PCR-based Kits

Nipah Virus Testing, End-User Outlook (Revenue - USD Million, 2019 - 2032)

  • Hospitals
  • Diagnostic Centers
  • Research Centers
  • Research Labs
  • Others

Nipah Virus Testing, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Nipah Virus Testing Market Report Scope

Report Attributes

Details

Market size value in 2023

USD 1,940.78 million

Revenue forecast in 2032

USD 3,036.68 million

CAGR

5.1% from 2023 – 2032

Base year

2022

Historical data

2019 – 2021

Forecast period

2023 – 2032

Quantitative units

Revenue in USD million and CAGR from 2023 to 2032

Segments covered

By Sample, By Product Type, By End-User, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Lupin Ltd., Starlake Bioscience, MyBioSource, Krishgen Biosystems, Roche Diagnostics, Aurobindo, Novartis AG, Bio-Rad Laboratories Inc., Xaretto, Liferiver, Merck KGaA, Vivacure, Minapharm, Creative Diagnostics, Luminex Corporation, Quidel Corporation, F. Hoffmann-La Roche Ltd., Abbexa Ltd., GenMark Diagnostics Inc., Seegene Inc., and Hologic Inc.

For Specific Research Requirements

Request for Customized Report

License and Pricing

Purchase Report Sections

  • Regional analysis
  • Segmentation analysis
  • Industry outlook
  • Competitive landscape
Request for Discount Pricing